Latest Breaking News On - Indolent lymphoma - Page 1 : comparemela.com

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Gloria leslieJohn theurer cancer centerChronic lymphocytic leukemia research programsHackensack meridian school of medicineIndolent lymphomaHackensack meridian school

CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.

Gloria leslieJamesk mccloskeyLori leslieJohn theurer cancer centerPeer exchangeResearch programsHackensack university medical centerHackensack university medicalAssociate professorIndolent lymphoma

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Lori leslieJamesk mccloskeyGloria lesliePeer exchangeResearch programsJohn theurer cancer centerHackensack university medical centerHackensack university medicalAssociate professorIndolent lymphomaMash 2023Zuma 7Axi celLargeb cell lymphomaOlder populationCart cell therapy

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Lori leslieJamesk mccloskeyGloria leslieHackensack university medical centerJohn theurer cancer centerResearch programsPeer exchangeHackensack university medicalAssociate professorIndolent lymphomaWhile brutonMash 2023Sympatico studySympatico trialMantle cell lymphomaBtk inhibitors

Pirtobrutinib Approval Adds Effective Third-Line Option to Previously Treated CLL/SLL Armamentarium

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes.

United statesNew jerseyEli lillyGloria leslieHackensack meridian school of medicineNational comprehensive cancer networkHackensack meridian healthIndolent lymphomaChronic lymphocytic leukemia research programsJohn theurer cancer centerHackensack meridian schoolHackensack meridianCart cell therapyJohn theurer cancer center of hackensack meridian healthHackensack meridian school of medicineThird line